Nvidia (NVDA) announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. Part of Nvidia AI Foundations, the new BioNeMo Cloud service offering – for both AI model training and inference – accelerates the most time-consuming and costly stages of drug discovery. It enables researchers to fine-tune generative AI applications on their own proprietary data, and to run AI model inference directly in a web browser or through new cloud application programming interfaces that easily integrate into existing applications. Amgen (AMGN) is already using the service to advance its research and development efforts.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVDA:
- Nvidia Stock: GTC Confirms the AI Opportunity, but the Goodness Is Priced in, Says Deutsche Bank
- Nvidia (NASDAQ:NVDA) Dodges China Chip Restrictions with H800
- Nvidia Struts its AI Stuff with New Plans
- NVIDIA and Google Cloud Deliver Powerful New Generative AI Platform, Built on the New L4 GPU and Vertex AI
- NVIDIA Expands Omniverse Cloud to Power Industrial Digitalization